May. 2 at 2:59 PM
$QNTM
• MS Market Opportunity — Lucid-MS’s first-in-class myelin-protective approach (non-immunosuppressive) could command premium pricing if it slows progression or aids repair.
• Biotech Precedents — Positive Phase 2 data in neurology/MS or rare diseases often drives 5–20x+ gains for small caps, especially with Big Pharma interest. Later-stage or partnered assets in CNS can reach multi-billion valuations.
• Risk-Adjusted Reality — Valuations would still discount for Phase 3 risks, competition, and capital needs. Full buyout multiples in recent CNS/neuro deals often fall in the
$1–15B range for more advanced assets.
Key Drivers of Higher Value
• Robust efficacy on clinical endpoints or strong biomarkers (e.g., neurofilament light chain, MRI myelin measures).
• Clean safety profile (critical in MS).
• Partnership or acquisition interest from players like Biogen, Novartis, or others active in MS/neuro.
This is speculative and highly dependent on the actual data readout.
